Conatus Pharmaceuticals
Jan 30, 2020
Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey
A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has managed to net USD 2 million more by offering 40% more shares. The company plans to use the funds raised to address the unmet needs in the Alzheimer’s disease market...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
